Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$30.24 -0.8%	$24.38	$20.39 ▼ $53.96	$1.41B	0.76	572,102 shs	208,009 shs
HROW Harrow	$39.02 +0.6%	$34.36	$20.85 ▼ $59.23	$1.44B	0.41	482,411 shs	252,819 shs
JANX Janux Therapeutics	$23.01 -1.5%	$24.53	$21.97 ▼ $71.71	$1.38B	2.86	928,672 shs	272,222 shs
NWBO Northwest Biotherapeutics	$0.30 +16.0%	$0.25	$0.17 ▼ $0.48	$452.91M	-1.14	3.38 million shs	21.27 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	+0.49%	+2.94%	+37.10%	+18.92%	-37.11%
HROW Harrow	+0.57%	+1.46%	+11.27%	+42.61%	-10.62%
JANX Janux Therapeutics	-1.23%	-6.11%	-8.61%	-2.87%	-48.31%
NWBO Northwest Biotherapeutics	+8.33%	+9.24%	+3.34%	-3.17%	-21.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	3.396 of 5 stars	1.2	1.0	3.7	3.6	4.2	1.3
HROW Harrow	3.4433 of 5 stars	4.6	1.0	0.0	3.2	2.5	0.6
JANX Janux Therapeutics	2.5531 of 5 stars	3.5	3.0	0.0	3.0	1.7	0.0
NWBO Northwest Biotherapeutics	0.3489 of 5 stars	0.0	3.0	0.0	3.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.40	Hold	$31.60	4.50% Upside
HROW Harrow	3.13	Buy	$64.67	65.74% Upside
JANX Janux Therapeutics	3.08	Buy	$86.90	277.74% Upside
NWBO Northwest Biotherapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NWBO, JANX, AMPH, and HROW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	AMPH Amphastar Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$28.00 ➝ $32.00
8/18/2025	JANX Janux Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
8/14/2025	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/14/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $63.00
8/13/2025	HROW Harrow	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $64.00
8/12/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$36.00
8/8/2025	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.00
7/11/2025	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$76.00
7/11/2025	JANX Janux Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
6/12/2025	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$62.00
6/10/2025	HROW Harrow	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$722.68M	1.95	$4.99 per share	6.06	$16.29 per share	1.86
HROW Harrow	$199.61M	7.23	$0.14 per share	282.07	$1.33 per share	29.34
JANX Janux Therapeutics	$10.59M	130.54	N/A	N/A	$16.48 per share	1.40
NWBO Northwest Biotherapeutics	$1.38M	328.20	N/A	N/A	($0.07) per share	-4.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.67	11.33	9.19	N/A	18.64%	20.76%	9.68%	11/5/2025 (Estimated)
HROW Harrow	-$17.48M	-$0.25	N/A	97.54	N/A	-4.49%	-2.18%	-0.35%	11/12/2025 (Estimated)
JANX Janux Therapeutics	-$68.99M	-$1.80	N/A	N/A	N/A	N/A	-11.48%	-11.01%	11/5/2025 (Estimated)
NWBO Northwest Biotherapeutics	-$83.78M	-$0.06	N/A	∞	N/A	-7,524.50%	N/A	-291.13%	11/14/2025 (Estimated)

Latest NWBO, JANX, AMPH, and HROW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NWBO Northwest Biotherapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.13 million
8/11/2025	Q2 2025	HROW Harrow	$0.01	$0.24	+$0.23	$0.13	$64.23 million	$63.74 million
8/7/2025	Q2 2025	JANX Janux Therapeutics	-$0.48	-$0.55	-$0.07	-$0.55	$0.30 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	3.29	2.21
HROW Harrow	0.78	0.62	0.58
JANX Janux Therapeutics	N/A	47.03	47.03
NWBO Northwest Biotherapeutics	N/A	0.07	0.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
HROW Harrow	72.76%
JANX Janux Therapeutics	75.39%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
HROW Harrow	15.16%
JANX Janux Therapeutics	8.10%
NWBO Northwest Biotherapeutics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	46.50 million	33.71 million	Optionable
HROW Harrow	180	37.00 million	31.39 million	Optionable
JANX Janux Therapeutics	30	60.09 million	55.23 million	Optionable
NWBO Northwest Biotherapeutics	20	1.49 billion	1.36 billion	Not Optionable

NWBO, JANX, AMPH, and HROW Headlines

Recent News About These Companies

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

August 27 at 1:30 PM | finanznachrichten.de

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

August 27 at 12:39 PM | prnewswire.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?

August 24, 2025 | marketbeat.com

Northwest Biotherapeutics announces passing of general counsel Les Goldman

August 19, 2025 | msn.com

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

August 18, 2025 | prnewswire.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Earnings Results

August 16, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Passes Below 200-Day Moving Average - Here's Why

August 15, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?

August 7, 2025 | marketbeat.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50-Day Moving Average - Here's What Happened

July 29, 2025 | marketbeat.com

NWBO - Northwest Biotherapeutics Inc News - Morningstar

July 11, 2025 | morningstar.comM

Northwest Biotherapeutics, Inc. (NWBO) - Yahoo Finance

June 29, 2025 | uk.finance.yahoo.com

NWBO Northwest Biotherapeutics, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 13, 2025 | finanznachrichten.de

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

June 11, 2025 | prnewswire.com

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

April 22, 2025 | seekingalpha.com

Citadel Securities, Virtu Must Face Biotech Stock Spoof Suit (1)

March 29, 2025 | news.bloomberglaw.comN

Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments

January 13, 2025 | msn.com

Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing

December 26, 2024 | prnewswire.com

Northwest Biotherapeutics: All Is Not Well With This One

December 14, 2024 | seekingalpha.com

Behind the Bell: Arcutis Biotherapeutics

November 5, 2024 | nasdaq.com

Northwest Registered Agent Review 2024: Features, Pricing & More

October 24, 2024 | forbes.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NWBO, JANX, AMPH, and HROW Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$30.24 -0.25 (-0.83%)

Closing price 03:59 PM Eastern

Extended Trading

$30.26 +0.02 (+0.06%)

As of 04:04 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Harrow NASDAQ:HROW

$39.02 +0.23 (+0.58%)

Closing price 03:58 PM Eastern

Extended Trading

$39.38 +0.36 (+0.92%)

As of 04:04 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Janux Therapeutics NASDAQ:JANX

$23.00 -0.35 (-1.48%)

Closing price 03:59 PM Eastern

Extended Trading

$23.05 +0.05 (+0.20%)

As of 04:04 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Northwest Biotherapeutics OTCMKTS:NWBO

$0.30 +0.04 (+16.04%)

As of 03:42 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time